Abstract---The emergence and spread of Gram-negative bacteria namely Acinetobacter baumannii, is a serious public health challenge worldwide due to antibiotics resistance. Infections caused by this bacterium demonstrated significantly high economic burden. Nevertheless, economic burden of carbapenem resistant-Acinetobacter
baumannii (CR-AB) and carbapenem susceptible -Acinetobacter baumannii (CS-AB) infections in Indonesia remain unknown. The aim of the study was to evaluate the cost of hospitalized patients associated with CR-AB and CS-AB infections. Methods: In a retrospective observational case control study, we evaluated the medical records of patients with CR-AB and CS-AB infections hospitalized in the Dr. Soetomo Hospital Surabaya, Indonesia between 2018-2021. Also, we retrieved the data of sex, clinical specimen, dates of admission and discharge. The study outcome was hospital costs such as antibiotic and diagnostic costs including radiology and lab investigations charges from the payer perspective. Results: The antibiotic and diagnostic costs for CR-AB infection was higher than CS-AB infection, US$ 1039.3 versus US$ 492.2 (p < 0.001). It showed that the CR-AB antibiotic cost was higher than CS-AB, US$ 77.2 versus US$ 19.7 (p < 0.001), and the CR-AB diagnostic cost was higher than CS-AB, US$ 882.1 versus US$ 463.1 (p < 0.05). Conclusion: The economic burden for hospitalized patients with CR-AB infection was higher compared to the hospital cost for CS-AB infections.

**Keywords**---Acinetobacter baumannii, Carbapenem-resistance, Hospital cost, Indonesia, Infectious diseases.

**Introduction**

*Acinetobacter baumannii* is the major cause of Health care associated infections worldwide (Dijkshoorn et al., 2007) and resistant to carbapenem which is the urgent global threat (Hamidian and Nigro, 2019). *Acinetobacter baumannii* is a most frequently isolated bacterium, resistant to multiple antibiotics (El Tahawy and Khalaf, 2013) and is a core cause of infections particularly ventilator-associated pneumonias in hospital settings (Munoz-Price and Weinstein, 2008). Dissemination of *Acinetobacter baumannii* infections is widespread in a clonal manner with in the hospital or to the other hospitals, it is evident that it increases the length of stay and hospital cost (Peleg et al., 2008). The *Acinetobacter baumannii* infections are in WHO 1st priority critical pathogen list, associated with increased clinical and economic burden and multidrug resistant specifically carbapenem which is last resort to treat it (World Heath Organization, 2017).

The increase prevalence of carbapenem resistant-*Acinetobacter baumannii* (CR-AB) is the major cause of mortality in hospital acquired infections (Rossi et al., 2019). CR-AB infections are itself a risk factor of hospital admitted patients and put a heavy burden on total hospital cost (Zhen et al., 2017). According to China study CR-AB infection put significant burden on hospital cost and is associated with high mortality (Huang et al., 2016), another study stated that CR-AB hospitalization cost was higher than carbapenem-susceptible *Acinetobacter baumannii* (CS-AB) and have impact on hospital cost (Lemos et al., 2014).

The burden of healthcare-associated infections (HAI) are significantly higher in low- and middle-income than in high-income countries (Maki and Zervos, 2021).
The rate of CR-AB was highest in south east Asia including Indonesia (LY et al., 2017). Indonesia is fourth most populated country worldwide (The World Bank, 2022). Although Indonesia has very limited data on CR-AB and its hospital cost. However, the Studies from indonesia reported the CR-AB highly prevalent in the hospitals (Karuniawati et al., 2011; Saharman et al., 2018). In this study, we estimated the antibiotics and diagnostic cost of carbapenem resistant *Acinetobacter baumannii* hospitalized patients.

**Materials and Methods**

**Study design, setting and duration**

The retrospective case control study was carried out at department of microbiology, Dr. Soetomo Hospital, Surabaya Indonesia during period March 2018 to February 2021. It is a general academic hospital with 1514 beds and 26 departments, serving the community of eastern Indonesia. This study was approved by the Ethics Review Committee (ERC) of Dr. Soetomo Hospital, Surabaya Indonesia vide letter No. 0188/KEPK/IV/2021 dated 29th Aprill 2021.

**Selection criteria**

We reviewed the medical records of all those patients who hospitalized in Dr Soetomo Hospital, Surabaya, Indonesia during the period from March 2018 to February 2021. Total 198 patients including 66 with caused by CR-AB and 132 patients caused by CS-AB, were selected. Other criteria included age ≥18 years, males and females, COVID-19 negative, admitted in surgical, medical, and ICU wards were included in the study.

**Data collection**

The retrospective data such as gender, clinical specimen, carbapenem status, antibiotic cost, diagnostic cost, dates of admission & discharge retrieved. Outcomes of interest were hospitalization cost such as diagnostic cost and antibiotic cost. Diagnostic cost included radiology and lab investigations charges like Clinical pathology, pathology anatomy and clinical microbiology from the payer perspective

**Statistical analysis**

Data were managed through IBM Statistics SPSS version 20.0. Data for gender, organism, specimen and other drugs susceptibility was described by using frequency and percentages and comparison between two groups by carbapenem resistance was performed by using Chi-square and likelihood ratio test. Data of costs for different factors were described by using median (IQR) for groups by carbapenem resistance status, and comparison between groups was made by using Mann Whitney U test. The comparison among two groups by carbapenem status using Kruskal Wallis followed by Mann Whitney for pairwise comparison. resistant and sensitive cases were made by using Mann Whitney U test. P-value ≤ 0.05 was considered significant.
Results

This study was started in January 2021 until August 2021. The data was extracted from electronic medical record since March 2018 until February 2021. Total 198 cases included in the study and of them 66 (33.3%) cases were found carbapenem-resistant. The frequency of carbapenem-resistant cases was higher in males than females. However, the difference between two genders was insignificant (51.5 % vs. 47.7 %; P > 0.05). Among clinical specimens, carbapenem-resistant cases were more frequent in Blood (60.6%), followed by urine (31.8%), CSF (4.5%) and pleural fluid (3.0 %). However, the frequency of carbapenem-resistant cases was not significantly different across different specimens with p>0.05. (Table 1)

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Acinetobacter baumannii</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Susceptible</td>
<td>Resistant</td>
</tr>
<tr>
<td></td>
<td>Count</td>
<td>%</td>
</tr>
<tr>
<td>Urine</td>
<td>66</td>
<td>50.0</td>
</tr>
<tr>
<td>Blood</td>
<td>43</td>
<td>32.6</td>
</tr>
<tr>
<td>Pleural Fluid</td>
<td>10</td>
<td>7.6</td>
</tr>
<tr>
<td>CSF</td>
<td>5</td>
<td>3.8</td>
</tr>
<tr>
<td>Peritoneal</td>
<td>5</td>
<td>3.8</td>
</tr>
<tr>
<td>Pericardial</td>
<td>3</td>
<td>2.3</td>
</tr>
</tbody>
</table>

For CR-AB cases, the total median cost for antibiotics was $77.2 and for CS-AB cases $19.7. The CR-AB had significantly higher median cost of antibiotics as compared to carbapenem susceptible with p-values < 0.001. For CR-AB cases, the diagnostic total median cost was $882.1 and for CS-AB cases the diagnostic total median cost was $463.1. The CR-AB had significantly higher diagnostic median cost as compared to carbapenem susceptible with p-values < 0.001 (Table.2)

<table>
<thead>
<tr>
<th>Hospital cost</th>
<th>Acinetobacter baumannii</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Susceptible</td>
<td>Resistant</td>
</tr>
<tr>
<td></td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
</tr>
<tr>
<td>Antibiotic</td>
<td>19.7 (6.5 - 47.3)</td>
<td>77.2 (27.5 - 253.0)</td>
</tr>
<tr>
<td>Diagnostic</td>
<td>463.1 (335.9 - 786.4)</td>
<td>882.1 (564.7 - 1343.4)</td>
</tr>
<tr>
<td>Total</td>
<td>492.2(362.5 – 925.2)</td>
<td>1039.3 (615.7 – 1562.1)</td>
</tr>
</tbody>
</table>

Statistically significant, p <0.05
Discussion

In 1911 the *Acinetobacter* was first defined by Micrococcus calco-aceticus, in 1950 becomes *Acinetobacter* (Silvia Munoz-Price and Weinstein, 2008). This bacterium becomes difficult to control because of its airborne transmission and survive in very depraved environment (Bernards et al., no date; Wagenvoort and Joosten, 2002; Falagas et al., 2008). The Carbapenems are the most effective antibiotics for the treatment of *Acinetobacter baumannii* (Qureshi et al., 2015; Ozsurekci et al., 2017). Carbapenem resistance has increasingly worldwide (Nordmann and Poirel, 2019). However, in Indonesia, very little is known about costs associated with CR-AB versus CS-AB. We found that compared with CS-AB with CR-AB were associated with significantly increased hospital costs, as Zhen et al. reported that the carbapenem-resistant *Acinetobacter baumannii* hospital cost was higher than the carbapenem susceptible (Zhen et al., 2020). Similar to this study CRAB hospital charges increases after culture due to prolong stay (Lautenbach et al., 2009). The present study showed higher diagnostic and antibiotics cost of CRAB than CSAB likewise Zhen et al. calculated higher laboratory cost, antibiotics cost and may have contributed to higher total medical cost (Zhen et al., 2017). In the same way Yang et al. found that miss use of antibiotics could increases cost of the hospital (Yang et al., 2010). Without confirmation by antibiotics sensitivity test the prescription of antibiotics in hospital in patients not only increases the burden on hospital cost (Bimba et al., 2020), also increases the resistance (Ayukekbong et al., 2017). The continues same findings were found from last ten years previous studies that the carbapenem resistance was linked with increase economic costs for infections caused by gram-negative bacteria, specifically *Acinetobacter baumannii*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* (Lautenbach et al., 2009; Tian et al., 2016; Ayukekbong et al., 2017; Bimba et al., 2020). Our results showed the diagnostic and antibiotics cost of CRAB higher than CSAB as in some studies shows that inpatients with serious illness probably have multiple diagnosis, treat with different kind of antibiotics compare with outdoor patients (Jiao et al., 2015; Judd et al., 2016), all these lead to spread of carbapenem resistance and ultimately increase the cost of the hospital. Our study some limitations are worth noting, it’s a single centre study and total hospital cost such as bed, pharmacy and administration cost was not included in this study. To provide complete view related to infections cost of the hospital should include all kind of cost expenditure use during stay in hospital and expand this study to multicentre in different areas.

Conclusions

Our study concluded that the CRAB antibiotics and diagnostic cost were higher than the CSAB. Further studies are needed to explore and regulate to early diagnosis and identification of infectious organisms. Early treatment ultimately reduces the extra burden on hospital cost.

Author Contributions


**Funding:** The study was funded by Indonesian Ministry of Higher Education and Technology Republic of Indonesia (Grant No.282/UN3.15/PT/2021).

**Institutional Review Board Statement:** This study was approved by the Research ethical committee Dr. Soetomo Hospital, Surabaya, (No. 0188/KEPK/IV/2021).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study

**Data Availability Statement:** The data will be provided upon reasonable request from the corresponding author.

**Acknowledgments:** I thankfully acknowledge to Dr. Farizal for his support and helping me in this study. Thanks for Doctoral research grant from Ministry of Higher Education, Research and Technology, Republic of Indonesia. Also, thanks to Dr. Soetomo hospital Surabaya and Laboratory of Medical Microbiology Faculty of Medicine University of Airlangga for facilitating this study.

**Conflicts of Interest:** The authors declare that there is no conflict of interest to disclose

**References**


‘Acinetobacter infections: a growing threat for critically ill patients’,
Epidemiology and infection, 136(8), pp. 1009–1019.
doi:10.1017/S0950268807009478.
Hamidian, M. and Nigro, S.J. (2019) ‘Emergence, molecular mechanisms and
global spread of carbapenem-resistant Acinetobacter baumannii’, Microbial
Genomics, 5(10). doi:10.1099/MGEN.0.000306.
Huang, W., Zong, Z., Qiao, F., Chen, Y., Yin, W., Dong, P. and Lin, J. (2016)
‘DIRECT ECONOMIC BURDEN AND OUTCOMES AMONG PATIENTS WITH
CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION OR
‘Risk factors for carbapenem-resistant Klebsiella pneumoniae
infection/colonization and predictors of mortality: a retrospective study’,
Pathogens and Global Health, 109(2), p. 68.
doi:10.1179/2047773215Y.0000000004.
‘Clinical and economic impact of meropenem resistance in Pseudomonas
aeruginosa–infected patients’, American Journal of Infection Control, 44(11),
Karuniawati, A., Lestari, Delly Chipta, Zorgani, A., Saharman, Y.R. and Lestari,
Delly C (2011) ‘Detection of carbapenemase encoding genes in
Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumanii
isolated from patients at Intensive’, academia.edu, 2, pp. 101–106. Available
at:
Lautenbach, E., Synnestvedt, M., Weiner, M.G., Bilker, W.B., Vo, L., Schein, J.
Acinetobacter baumannii’, Infection control and hospital epidemiology, 30(12),
Lemos, E. V., de la Hoz, F.P., Alvis, N., Einarson, T.R., Quevedo, E., Castañeda,
carbapenem resistance on clinical and economic outcomes among patients
with Acinetobacter baumannii infection in Colombia’, Clinical Microbiology and
Acinetobacter baumannii and Enterobacteriaceae in South and Southeast
Middle-Income Countries and the Role of Infection Prevention and Control’,


